Antineoplastic Agents, Immunological
"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000074322
|
| MeSH Number(s) |
D27.505.954.248.384
|
| Concept/Terms |
Antineoplastics, Monoclonal Antibodies- Antineoplastics, Monoclonal Antibodies
- Antibodies Antineoplastics, Monoclonal
- Monoclonal Antibodies Antineoplastics
- Monoclonal Antibodies, Antineoplastic
- Antineoplastic Monoclonal Antibodies
- Antineoplastic MAbs
- Antineoplastics, Monoclonal Antibody
- Monoclonal Antibody Antineoplastics
- MAbs, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".
This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 4 | 1 | 5 |
| 2018 | 12 | 4 | 16 |
| 2019 | 9 | 4 | 13 |
| 2020 | 12 | 4 | 16 |
| 2021 | 8 | 5 | 13 |
| 2022 | 4 | 1 | 5 |
| 2023 | 3 | 0 | 3 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.
-
Association of the time of day of chemoradiotherapy and durvalumab with tumor control in lung cancer. Radiother Oncol. 2025 Feb; 203:110658.
-
HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25; 15(1):10213.
-
Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan; 31(1):176-188.
-
Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011. Cancer. 2025 Jan 01; 131(1):e35601.
-
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov; 41(11):4125-4139.
-
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. J Thorac Oncol. 2025 Jan; 20(1):109-118.
-
Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis. Ann Med. 2024 Dec; 56(1):2396559.
-
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. J Am Acad Dermatol. 2025 Jan; 92(1):68-77.
-
First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study. Eur Urol. 2024 Dec; 86(6):503-512.
-
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood Cancer J. 2024 08 07; 14(1):129.